Related Experiment Video
Updated: May 31, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
New-generation diabetes management: glucose sensor-augmented insulin pump therapy
Eda Cengiz1, Jennifer L Sherr, Stuart A Weinzimer
1Pediatric Endocrinology and Diabetes, Yale School of Medicine, New Haven, CT 06520, USA. eda.cengiz@yale.edu
Expert Review of Medical Devices
|July 7, 2011
Summary
Technological advancements in diabetes care, like continuous glucose monitoring and insulin pumps, have evolved into sensor-augmented insulin pump therapy. This innovation is key for developing artificial pancreas systems for better diabetes management.
Area of Science:
- Endocrinology
- Medical Technology
- Diabetes Management
Background:
- Diabetes mellitus is a prevalent chronic disease with rising global incidence.
- Technological innovations offer improved tools for managing diabetes.
- Continuous subcutaneous insulin infusion and continuous glucose monitoring have advanced diabetes care.
Purpose of the Study:
- To summarize the evolution of sensor-augmented insulin pump therapy.
- To discuss the current state and future applications of this technology.
- To highlight its role in developing artificial pancreas systems.
Main Methods:
- Review of technological advancements in diabetes management.
- Analysis of the integration of continuous glucose monitors and insulin pumps.
- Discussion of sensor-augmented insulin pump therapy's development.
Main Results:
- Continuous subcutaneous insulin infusion systems refine insulin delivery.
- Continuous glucose monitors enhance understanding of glucose variability.
- Sensor-augmented insulin pump therapy integrates these technologies.
Conclusions:
- Sensor-augmented insulin pump therapy is a foundational element for artificial pancreas development.
- This therapy represents a significant step forward in diabetes management.
- Future applications promise enhanced, next-generation diabetes care.
Related Concept Videos
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Insulin and C-peptide are co-secreted in...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...